The development of specific therapies targeting driver alterations (e.g., EGFR mutations or ALK and ROS1 rearrangements) has changed the treatment paradigm and natural history of non-small cell lung cancer (NSCLC) harboring these aberrations [4,5]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.